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Summary To assess whether there is an additive effect between chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection on the
development of hepatocellular carcinoma (HCC), 400 consecutive cirrhotic patients were followed prospectively with periodic abdominal
ultrasound examination and measurement of serum a-fetoprotein (AFP) level every 4 months. During a follow-up of 1185 person-years, 80
(20%) patients developed HCC, with an annual incidence of 6.8%. The annual incidence was 2.0% in patients negative forhepatitis B surface
antigen (HBsAg) and antibodies to HCV (anti-HCV), 6.6% in patients with HBsAg alone, 7.0% in patients with anti-HCV alone and 13.3% in
patients co-infected with HBV and HCV. There was a positive linear trend in the annual incidence of HCC among patients without either
marker, patients with single viral infection and patients with dual viral infection (Pfortrend < 0.0001). Cox's proportional hazard model indicated
that HCV/HBV co-infection [hazard ratio (HR), 6.41; 95% confidence interval (Cl), 1.80-22.80], anti-HCV alone (HR, 3.74; 95% Cl,
1.07-13.07) and HBsAg alone (HR, 4.06; 95% Cl, 1.23-13.34) were independently riskfactors of HCC. In conclusion, there is an additive and
independent effect modification of HCV and HBV infection on HCC development.
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Hepatocellular carcinoma (HCC) is one of the most common
primary malignant tumours of the liver. Interest in HCC derives
not only from its worldwide distribution but also from evidence
implicating hepatotropic viruses in its development (Simonetti et
al, 1991; Colombo, 1995; Sherlock and Dooley, 1997). Molecular,
retrospective and prospective epidemiological and clinical studies
in human beings, hepadnavirus-infected animals and transgenic
mice models have confirmed the strong association that exists
between chronic hepatitis B virus (HBV) infection and the occur-
rence ofHCC (Simonetti etal, 1991; Jeng andTsai, 1991; Tsai etal,
1994a-d, 1996a; Colombo, 1995; Moradpour and Wand, 1996).
The sequential development ofcirrhosis and HCC in patients with
post-transfusion hepatitis (Kiyosawa et al, 1990; Tong et al, 1995)
and the high prevalence of antibodies to hepatitis C virus (anti-
HCV) in patients with HCC are clues leading to the identification
ofHCV carriers as another important patient population at risk for
HCC (Jeng and Tsai, 1991; Simonetti et al, 1991; Tsai et al,
1994a-d, 1996a). Persistent infection and chronic liver disease are
hallmarks of HCV infection (Tsai et al, 1993, 1994e-g, 1995a,b,
1996b, 1997; Sherlock and Dooley, 1997). Although HCC may
occasionally develop in a normal liver, most cases are associated
with long-lasting chronic liver disease (Sherlock and Dooley,
1997). Between 2.2% and 55% ofautopsied cirrhotic patients have
HCC, and about 80% of HCC patients have coexisting cirrhosis
(Jeng and Tsai, 1991; Simonetti et al, 1991; Tsai et al, 1994a-d,
1996a; Sherlock and Dooley, 1997). Because the majority ofHCC
arises in the cirrhotic liver, and because cirrhosis seems to be a
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major determinant or promoting factor in the development of
HCC, recognition ofthe conditions associated with HCC develop-
ment can contribute to the knowledge ofhepatic carcinogenesis.
Although mostHBV- and/orHCV-infectedpatientsdevelop HCC
only after their disease has progressed to cirrhosis, it is unknown
whethertherisk ofprogression to HCC is different in relation to the
aetiology ofcirrhosis. Moreover, multiple viral infection frequently
occurs in patients with chronic liver disease. For example, around
10-20% ofchronic HBsAg carriers have been reported to be posi-
tive for anti-HCV, and 2-10% of anti-HCV-positive patients have
been reported to have markers ofHBV infection (Kaklamani et al,
1991; Simonetti et al, 1992; Tsai et al, 1993, 1994a-g, 1996a,b;
Benvegnu et al, 1994; Alberti et al, 1995). It is not certain whether
this co-infection increases the likelihood of the development of
HCC. Ourprevious case-control studies have shown thatthere is an
interacting role between HBV and HCV infection in the develop-
ment of chronic hepatitis (Tsai et al, 1996b), cirrhosis (Tsai et al,
1993, 1994a), and HCC (Tsai et al, 1994a-d, 1996a). A synergistic
interaction between HBV and HCV in thedevelopment ofHCC has
also been speculated by otherinvestigators (Kaklamani et al, 1991;
Simonetti et al, 1992). However, most previous studies have aimed
to explore the association between HCV/HBV and HCC and have
been limited to case-series studies (Jeng andTsai, 1991; Kaklamani
et al, 1991) or cross-sectional case-control studies (Simonetti et al,
1992; Tsai et al, 1994a-d, 1996a). Because blood samples for the
detection of viral markers were collected at the time and/or after
the diagnosis of HCC, these studies have left a controversy on
causal inferences. Moreover, reports assessing the incidence of
HCC development and its contributing factors in cirrhotic patients
related to hepatitis B and C are rare. Furthermore, the mutual
confounding and interactive effects between HBV and HCV infec-
tion remain to be elucidated. We have therefore conducted a
prospective study to explore these problems.
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SUBJECTS AND METHODS
Design of the study
This was a prospective study of a cohort of 400 consecutive
patients with non-alcoholic cirrhosis. At inclusion in the follow-
up, patients were evaluated for HBV and HCV markers, conven-
tional liver function tests, serum a-fetoprotein (AFP) levels and
Child-Pugh grades. The patients were followed up prospectively
to define the incidence of HCC development in relation to HBV
and HCV infection.
Study population
During a 6-year period, 400 consecutive patients with non-alco-
holic cirrhosis were prospectively followed, each for a minimum
of 4 months, after clinicopathological diagnosis at entry. All
patients were hospitalized or visited outpatients clinics in
Kaohsiung Medical College Hospital from January 1989 to
December 1994. There were 290 men and 110 women, with a
mean age of 52.0 ± 11.1 (mean ± SD) years. Cirrhosis was diag-
nosed by liver biopsy, abdominal sonography (portal systemic
shunts, splenomegaly, spotty coarse parenchyma, nodular surface
and dull or round edge), biochemical evidence of parenchymal
damage plus endoscopic oesophageal or gastric varices (Tsai et al,
1993, 1994a). Patients were classified into the three Child-Pugh
grades based on their clinical status (Pugh et al, 1973). Patients
with a possible association with HCC at the time of entry were
excluded. Written informed consent was obtained from each
subject studied. The study was approved by the Investigation and
Ethics Committee ofthe hospital.
Serological examination
At inclusion andduring the subsequent visits, serawere taken from
all patients. Hepatitis B surface antigen (HBsAg), anti-HCV and
AFP were tested with Ausria-II, second-generation HCV EIA and
a-feto RIABEAD (Abbott Laboratories, Chicago, IL, USA)
respectively. For anti-HCV, reactive specimens were re-tested.
Repeatedly reactive samples were tested with another second-
generation anti-HCV immunoassay (UBI HCV EIA; United
Biomedical, Lake Success, NY, USA), which incorporates
synthetic peptides from the capsid and non-structural protein
region as the solid-phase antigen. Only specimens reactive in all
three tests were considered as anti-HCV positive. Conventional
liver function tests were determined with an autoanalyser.
Follow-up of patients
Follow-up was done by periodic abdominal ultrasound examina-
tion every 4 months and more frequently if clinically indicated.
Routine follow-up studies included clinical assessment, conven-
tional liver biochemical tests, assay for AFP and real-time ultra-
sonography. If a space-occupying lesion of the liver was found
during follow-up and/or serum AFP was 2 400 ng ml-1 without
aminotransferase fluctuation, aspiration cytology or biopsy was
performed. The starting time was the day of enrolment. All prog-
nostic variables were measured on that day. Follow-up time was
defined as the duration from the date of enrolment to the date of
HCC development, the last contact with the patients or the end of
the observation period (December 31 1994). Forty-two (10.5%)
patients were lost to follow-up. Because the eventual outcomes
regarding the appearance of HCC were not identified in these
patients, they were dealt with as censored data in the following
statistics (Harrington and Fleming, 1982).
All HCC patients were diagnosed by fine-needle aspiration
cytology or biopsy. Ultrasound examination was performed with a
high resolution real-time instrument (Sonolayer SSA-250A,
Toshiba Corporation, Tokyo, Japan) with a 3.5-MHz convex trans-
ducer. Fine-needle biopsy was done under sonographic guidance
using 22G thin needles.
Statistical analysis
Continuous data were expressed as means ± standard deviation
(mean ± SD). The difference between means of unpaired contin-
uous variables was compared with unpaired Student's t-test and/or
one way analysis of variance with the Tukey's test when appro-
priate. Fisher's exact test was used to compare differences between
proportions. Relative risks with 95% confidence interval (95% CI)
were used to estimate associations between exposure and disease.
The Mantel extension test for trend was used to examine the
dose-response relationship for the risk estimates. Kaplan-Meier's
product limit survival analysis was performed to evaluate the
cumulative probability of HCC development in patients during
follow-up (Kaplan and Meier, 1958). Univariate analysis by the
Mantel-Cox log-rank test was used to define the influence of each
risk factor (Peto et al, 1974). Multivariate analysis by Cox's
proportional hazards model was used to evaluate the independent
roles of each factor (sex, age, AFP, HBsAg, anti-HCV, alanine
aminotransferase (ALT), and Child-Pugh stage) for development
of HCC (Cox, 1972). All factors found to be at least marginally
associated with HCC development (P < 0.15) were tested by
multivariate analysis. Two-tailed P-values and 95% CIs were
given when appropriate. An alpha of0.05 was used as the indicator
of statistical significance. Data analyses were performed with the
computer program BMDP/Dynamic, release 7.0 (BMDP
Statistical Software, Los Angeles, CA, USA).
RESULTS
Clinical characteristics of patients at enrolment
At the time ofenrolment, 83 (20.8%) patients had anti-HCV alone
and 234 (58.5%) patients had HBsAg alone. Forty (10.0%)
patients were positive for HBsAg and anti-HCV. Neither HBsAg
nor anti-HCV was positive in 43 (10.8%) patients. The mean age
of 123 patients with anti-HCV was greater than that of patients
negative for anti-HCV (57.0 ± 9.3 vs 50.0 ± 11.4 years,
P = 0.0001). Further analysis indicated that the mean age of
patients with HBsAg alone (49.0 ± 11.3 years) was lower than that
of patients with anti-HCV alone (58.8 ± 6.7 years, P < 0.01) or
patients with HBsAg and anti-HCV (56.0 ± 9.5 years, P < 0.01).
According to the Child-Pugh classification, grade A, B and C
were noted in 282 (70.5%), 100 (25.0%) and 18 (4.5%) patients
respectively. The frequency of Child-Pugh C in patients co-
infected with HBV/HCV infection (15.0%, 6/40) was higher than
that in patients negative for either marker (2.3%, 1 out of 43;
P = 0.044), in patients with HBsAg alone (3.4%, 8 out of 234;
P = 0.012) and in patients with anti-HCV alone (3.6%, 3 out
of 83; P = 0.014). There were 122 (30.5%) patients with initial
serum AFP greater than 20 ng ml-'.
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Table 1 Incidence of HCC development in cirrhotic patients by the status of HBsAg and anti-HCV
Development of HCC
HBsAg/anti-HCV at entry n Follow-up (years) Age (years) n (%) Annual incidence (%)
Negative/negative 43 3.2 ± 1.7a 56.3 ± 5.6 3 (7.0) 2.0de
Positive/negative 234 2.9 ± 1.8 52.6 + 7.9b,c 45 (19.2) 6.6d
Negative/positive 83 2.9 ± 1.3 62.9 ± 3.8b 17 (20.5) 7.0e
Positive/positive 40 2.8 ± 1.7 59.7 ± 8.8c 15 (37.5) 13.3d,e
Total 400 3.0± 1.7 56.2 ± 8.5 80 (20.0) 6.8
HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; anti-HCV, antibodies to hepatitis C virus. aContinuous data are
expressed as means + SD; b.cp < 0.01 (one-way analysis of variance with the Tukey test); d,ep < 0.0001 (Mantel extension test for trend).
Table 2 Incidence of HCC development during follow-up of 400 cirrhotic patients in relation to baseline clinical manifestations
Parameters Groups No cases at risk HCC developed
n (%) Relative risk (95% Cl)
Sex Men 290 65 (22.4) 1.8 (1.0-3.5)
Women 110 15 (13.6) 1.0
Age (years) .50 253 66 (26.1) 3.4 (1.7-6.5)
< 50 147 14 (9.5) 1.0
AFP (ng ml-') > 20 122 36 (29.5) 2.2 (1.3-3.8)
<20 278 44 (15.8) 1.0
ALT (IU I-1)a Normal (<45) 199 31 (15.5)
lXb<ALT<2.5x 113 23(22.1) -
> 2.5 x 88 26 (29.5) -
Child-Pugh A 282 55 (19.5) -
B 100 22 (22.0) -
C 18 3 (16.7) -
HBsAg Positive 274 60 (21.9) 1.5 (0.8-2.6)
Negative 126 20 (15.8) 1.0
Anti-HCV Positive 123 32 (26.0) 1.6 (1.0-2.9)
Negative 277 48 (17.3) 1.0
HCC, hepatocellular carcinoma; AFP, a-fetoprotein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; Anti-HCV,
antibodies to hepatitis C virus. ap< 0.01 (Mantel extension test fortrend); blX = 45 IU I-'
Development of HCC during follow-up
During a follow-up period of 1185 person-years (3.0 ± 1.7 years),
HCC was developed in 80 (20.0%) patients 2.8 ± 1.5 years after
entry into the study. Using the Kaplan-Meier method, the cumula-
tive frequency ofbeing free ofHCC was found to be 83.2% at the
end of the third year and 44.4% at the end of the sixth year. The
calculated annual incidence of HCC development was 6.8%. The
annual incidence was 2.0% in patients negative for HBsAg and
anti-HCV, 6.6% in patients with HBsAg alone, 7.0% in patients
with anti-HCV alone and 13.4% in patients co-infected with HBV
and HCV (Table 1). There was apositive lineartrend in the annual
incidence of HCC among patients without either marker, patients
with single viral infection and patients with dual viral infection
(Pfor trend < 0.0001; Table 1). Among cirrhotic patients who devel-
oped HCC, there were 65 men and 15 women. Their age ranged
from 33 to 74 (56.2 ± 8.5) years. When HCC was diagnosed, 30
(37.5%) patients had serum AFP level < 20 ng ml', 25 (31.3%)
patients had AFP level between 21 and 399 ng mll and another 25
(31.3%) patients had serum AFP greater than 400 ng ml-'. The size
of HCC at diagnosis was less than 2 cm in 26 (32.5%) patients,
between 2.1 cm and 3 cm in 41 (51.2%) patients, between 3.1 cm
and 4 cm in 7 (8.8%) patients and between 4.1 cm and 5.0 cm in 2
(2.5%) patients. Diffuse HCC was noted in 4 (5.0%) patients. The
median diameter ofHCC was 2.8 cm.
Development of HCC in relation to baseline clinical
features
As shown in Table 2, although male cirrhotic patients developed
HCC more frequently than did female cirrhotic patients, the differ-
ence was not significant. The frequency ofHCC development was
higher in those older than 50 years (P < 0.0001) and in patients
with serum AFP > 20 ng ml' (P < 0.003). There is a positive
linear trend in the incidence ofHCC as serum ALT level increased
(Pfor trend < 0.01) (Table 2). Although the frequency of HCC
development in HBsAg-positive (or anti-HCV-positive) cirrhotic
subjects was slightly higher than HBsAg-negative (or anti-HCV-
negative) cirrhotic subjects, the difference did not reach statistical
significance. However, the incidence of HCC development in
patients with concurrent HCV and HBV infection (37.5%) was
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Figure 1 Cumulative risk for free of hepatocellular carcinoma in relation to serum alanine aminotransferase and a-fetoprotein levels, Child-Pugh grade, and
age at enrolment. ALT, alanine aminotransferase; 1x = 45 IU 1-1; AFP, a-fetoprotein
higher than in patients with anti-HCV alone (20.5%, P < 0.04), in
patients with HBsAg alone (19.2%, P < 0.04) or in patients nega-
tive for either infection (7.0%, P < 0.001) (Table 1). There was a
linear trend in the incidence of HCC development among patients
negative for either viral marker, patients with each marker alone
and those with HBsAg and anti-HCV (Pfortrend < 0.0001; Table 1).
Univariate analysis of risk factors for HCC development
As shown in Figure 1, univariate analysis indicated that the cumu-
lative risk for HCC development was significantly higher in
patients older than 50 years (P = 0.0001), in those with AFP
> 20 ng ml-1 (P = 0.001) and in patients with raised ALT levels at
entry (P = 0.0001). Compared with patients with Child-Pugh A
disease, cirrhotic patients with Child-Pugh B or C have a signifi-
cantly higher incidence of developing HCC (P = 0.0001). The
cumulative risk of being free of HCC in relation to status of
HBsAg and anti-HCV is shown in Figure 2. Although patients
with anti-HCV had a higher risk ofHCC (P = 0.025), there was no
such difference regarding HBsAg status. Compared with patients
with at least one viral marker, cirrhotic subjects negative for
HBsAg and anti-HCV had a lower risk of HCC (P = 0.014). The
highest risk of HCC was noted in patients co-infected with HBV
and HCV (P = 0.005). There was no statistical difference in the
cumulative risk ofHCC with regard to sex (data not shown).
Multivariate analysis of risk factors for HCC
development
As shown in Table 3, multivariate analysis with Cox's proportional
hazard model indicated that concurrent HCV and HBV infection
(P = 0.004), anti-HCV alone (P = 0.030), HBsAg alone
(P = 0.020) raised ALT at entry (P = 0.001 for ALT < 2.5-fold
upper limit of normal and P = 0.0001 for ALT > 2.5-fold upper
limit of normal), Child-Pugh B (P = 0.0001) or Child-Pugh C
(P = 0.002), age 2 50 years (P = 0.0001), and AFP > 20 ng ml-1
(P = 0.002) were independent risk factors for HCC.
DISCUSSION
By using a formal epidemiological approach, this prospective
study provides evidence that concurrent-HBV and HCV infection
predisposes cirrhotic patients to a significantly higher risk of
HCC development than patients with single viral infection.
Furthermore, although both viruses do cause cirrhosis and eventu-
ally HCC directly or indirectly, the other factors also play some
role in cancer promotion in patients with cirrhosis. Continuous
necroinflammation of liver tissue, which was expressed by
elevated levels of AFP and ALT, and worsening Child-Pugh
grades were also significant promoting factors.
In this study, seropositivity of HBsAg and/or anti-HCV was
noted in 89.2% (357 out of400) of cirrhotic patients at enrolment
and in 93% (77 out of80) ofpatients with cirrhotic HCC (Table 1).
The strong association between HCC development and these two
viral infections indicates that HBV and HCV operate a strong
oncogenic effect on liver cells. Moreover, this longitudinal study
indicates that the incidence of HCC development in cirrhotic
patients with HBV/HCV co-infection (25%; 15 out of 60) was
higher than in those with HBsAg alone (14.5%; 40 out of 274;
P = 0.04). In a previous prospective study performed in an HCV
hyperendemic area, concurrent HBV and HCV infection was
found in 17.3% (8 out of46) ofHBsAg-positive cirrhotic patients
developing HCC and in 7.7% (15 out of 195) of cirrhotic patients
with HBsAg (Ikeda et al, 1993). Taiwan is an area hyperendemic
for HBV infection. This study indicates that the risk for HCC in
patients with HBV/HCV co-infection was also significantly higher
than that in those with single viral infection in a HBV hyper-
endemic area (Table 1). The precise mechanisms by which dual
HBV/HCV infection promotes tumour development remain to be
elucidated. Our results and most epidemiological studies indicate
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Table 3 Multivariate analysis of factors associated with the development of HCC in cirrhotic patients by Cox's
proportional hazard model
Variables Coefficient s.e. P-value Hazard rate (95% Cl)
Anti-HCV+ alone 1.32 0.63 0.030 3.74 (1.07-13.07)
HBsAg+ alone 1.40 0.60 0.020 4.06 (1.23-13.34)
Anti-HCV+/HBsAg+ 1.85 0.64 0.004 6.41 (1.80-22.80)
Raised ALT (< 2.5xa) 1.06 0.31 0.001 2.91 (1.58-5.36)
Raised ALT (> 2.5 x) 1.53 0.28 0.0001 4.63 (2.65-8.09)
Child-Pugh B 1.06 0.26 0.0001 2.90 (1.71-4.92)
Child-Pugh C 2.09 0.66 0.002 8.08 (2.20-29.65)
AFP >20 ng ml-' 0.74 0.23 0.002 2.11 (1.32-3.37)
Age > 50 years 1.39 0.31 0.0001 4.02 (2.19-7.40)
HCC, hepatocellular carcinoma; Anti-HCV, antibodies to hepatitis C virus; HBsAg, hepatitis B surface antigen; ALT,
alanine aminotransferase; AFP, a-fetoprotein; Cl, confidence interval. a lx = 45 IU I-'.
that circulating anti-HCV is present appreciably more often in
HBsAg-negative than in HBsAg-positive patients with HCC (Jeng
and Tsai, 1991; Kaklamani et al, 1991; Simonetti et al, 1992; Tsai
et al, 1994a-d, 1996a). These observations suggest that HCV is
particularly likely to be a causative factor for HCC in patients in
whom HBV cannot be incriminated. The impact ofHCV infection
in patients with chronic HBV infection has not been well charac-
terized. HCV infection may prolong the hepatic injury ofHBV and
progress to cirrhosis. Compared with patients with single HBV or
HCV infection, the significantly higher frequency ofpatients with
Child-Pugh C in our patients with cirrhosis alone indicates that
dual HBV/HCV infection causes more severe liver damage. This
observation confirms that liver disease in patients with multiple
hepatotropic virus infection tends to be more severe than in
patients with single infection (Tsai et al, 1993, 1994a, 1995a,b;
Alberti et al, 1995). It is well known that superinfection ofHBV in
a chronic HCV carrier can cause more severe hepatitis (and/or
fulminant hepatitis) and that the same holds true for chronic HBV
carriers who develop a HCV superinfection (Alberti et al, 1995).
Furthermore, case-control studies have indicated that dual infec-
tion with HCV and HBV has a much higher odds ratio for the
development of HCC (Kaklamani et al, 1991; Simonetti et al,
1992; Tsai et al, 1994a-d, 1996a; Alberti et al, 1996). Recently, a
prospective follow-up study in Italy suggested that dual HBsAg
and anti-HCV positivity in patients with cirrhosis is an indepen-
dent and significant determinant for the development of HCC
(Benvegnu et al, 1994). In addition, several studies on HCC
patients negative for seral HBsAg have indeed shown that a signif-
icant number ofpatients with seral anti-HCV have both HBV and
HCV genomic sequences in tumorous and non-tumorous liver
tissue (Paterlini et al, 1993; Diamaantis et al, 1994). On the other
hand, although HCV may cause more severe liver damage than
HBV (Tsai et al, 1994e, 1996b; Takano et al, 1995), our results
show no difference in the incidence of HCC between the two viral
infections. However, a significantly higher incidence of HCC in
chronic hepatitis C than in chronic hepatitis B was reported previ-
ously, and was attributed to more severe liver damage caused by
HCV infection (Takano et al, 1995).
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It is noteworthy that the mean age in HCC patients with anti-
HCV alone was older than that in patients with HBsAg alone
(Table 1). In populations in which HBV infection is endemic,
HCC develops at a younger age in patients with HBV-related
tumours than in those with HCV-related tumours (Jeng and Tsai,
1991; Tsai et al, 1994a-d, 1996a). The age difference suggests that
in an HBV-endemic area persistent HCV infection is acquired later
in life than is chronic HBV infection. At the time ofenrolment, the
mean age of our patients with anti-HCV was 7 years older than
anti-HCV negative patients. Further analysis indicated that
patients with HBsAg alone were significantly younger than
patients with anti-HCV alone or patients with dual HBV/HCV
infection. A similar trend has also been noted in patients who
developed HCC (Table 1). In Taiwan the HCV carrier rate in the
general population tended to be higher among older subjects (Tsai
et al, 1997), and most of the HBsAg carriers had been infected
perinatally or horizontally during early childhood (Chen 1993).
The concurrent HBV and HCV infection in our patients might be
caused by superinfection of HCV in previous chronic HBV
carriers. Although HBV alone may be sufficient for development
ofHCC, it seems probable that HBV may also act as an 'initiating'
factor through its capacity ofdisarranging cellular genes, whereas
HCV may behave as a 'promoting' factor by causing persistent
liver cell necrosis and regeneration, resulting in cirrhosis and/or
HCC (Moradpour and Wand, 1996).
It is worth noting that there is an association between higher
serum ALT activity and increased risk ofdeveloping HCC (Figure
1). This observation indicates that the degree of hepatic injury
culminating in cirrhosis also correlates with the increased risk for
HCC (Curley et al, 1995). In addition, the cumulative risk of
developing HCC was statistically higher in patients with wors-
ening Child-Pugh grades (Figure 1) (Ikeda et al, 1993; Diamantis
et al, 1994). A recent study also indicated significantly higher inci-
dence of HCC in patients with severe chronic active hepatitis
and/or cirrhosis than in those with histologically less severe liver
injury (Curley et al, 1995). Regardless of aetiology, chronic liver
cell injury and the associated inflammatory and regenerative
response constitute a preneoplastic process that will inevitably
evolve towards malignancy if sufficient time is allowed to elapse
(Popper, 1988; Moradpour and Wand, 1996; Sherlock and Dooley,
1997). It is reasonable to assume that persistent infection, contin-
uous liverdamage and cirrhosis are the mostprobable mechanisms
by which HBV/HCV contribute to the pathogenesis ofHCC.
The yearly incidence of HCC in cirrhotics was from 2 to 5% in
the West, compared with 6-11% in the Far East (Colombo, 1995).
The calculated annual incidence ofHCC in this study is 6.8%. The
incidence ofHCC generally increases inproportion to age (Takano
et al, 1995). Ourresult also indicates that age greater than 50 years
is an independent risk factor for HCC (Table 2 and Figure 1). Age
may be either a determinant in itself or simply a reflection of the
duration of the liver disease (Simonetti et al, 1991). There is
evidence that HCC risk shows a linear increase during a patient's
lifetime (Takano et al, 1995). Consistent with this fact is the obser-
vation that the cumulative probability of developing HCC gradu-
ally increases during follow-up. In addition, a high AFP value at
enrolment was also a predictor for HCC (Table 2 and Figure 1). A
similar observation has also been reported previously (Tanano et
al, 1995; Sherlock and Dooley 1997). Although the mechanism of
the increase in serum AFP level in benign liver disease is complex
and not understood, this increase has been related to more aggres-
sive histological activity in chronic liver disease (Collazos et al,
1992). This observation supports the hypothesis that more severe
hepatic inflammation is a risk factor for liver cancer.
In conclusion, we have shown frequent coexistence ofHBV and
HCV markers in Chinese patients with cirrhosis and/or cirrhotic
HCC. We think that infection with HBV and HCV increases the
risk of more severe liver disease than infection with single viral
infection. We also provide evidence of the independent role and
additive interaction ofHBV and HCVinfection on thedevelopment
of HCC. Equally important is the fact that the degree of hepatic
injury culminating in cirrhosis also correlates with the increased
risk of HCC. The results of this and other studies indicate that
patients with HBV/HCV co-infection should be monitored with
great care for HCC development. Adequate treatment of chronic
HBV/HCV infection may decrease risk ofHCC development.
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